SCAI 2026 The End of Watchful Waiting: Long Term TAVR Evidence and a New Proactive Paradigm-The Latest Data on TAVR Durability: Lifetime Management, Dr. Ibrahim

The Latest Data on TAVR Durability: Lifetime Management, Dr. Ibrahim

Video Transcription

Video Summary

The speaker presents a 67-year-old obese man with severe aortic stenosis and moderate LAD disease, discussing whether surgical AVR or TAVR is best. He reviews low-risk trial data: PARTNER 3 showed the balloon-expandable Sapien 3 TAVR remained comparable or better than surgery at up to seven years, with no difference in valve failure or reintervention. Evolut Low Risk was initially noninferior, but longer-term results showed more reintervention and worse durability, likely due to older valve design and post-dilation issues. Considering lifetime management, he chooses TAVR with a Sapien 3 Resilia valve, achieving excellent hemodynamics and preserving future coronary access.

Asset Caption

closed captions are computer-generated

Keywords

aortic stenosis

TAVR

aortic

TAVI

surgical AVR

PARTNER 3

Sapien 3 Resilia